Changchun BCHT Biotechnology Co. A
Changchun BCHT Biotechnology Co. Ltd., a biopharmaceutical company, engages in the research and development, production, and sale of human vaccines in China and internationally. The company's products include herpes zoster vaccine; varicella vaccine; live, nasal, and freeze-dried influenza vaccine; and rabies vaccine (vero cell) for humans. Changchun BCHT Biotechnology Co. Ltd. was founded in 200… Read more
Changchun BCHT Biotechnology Co. A (688276) - Total Assets
Latest total assets as of September 2025: CN¥5.21 Billion CNY
Based on the latest financial reports, Changchun BCHT Biotechnology Co. A (688276) holds total assets worth CN¥5.21 Billion CNY as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Changchun BCHT Biotechnology Co. A - Total Assets Trend (2017–2024)
This chart illustrates how Changchun BCHT Biotechnology Co. A’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Changchun BCHT Biotechnology Co. A - Asset Composition Analysis
Current Asset Composition (December 2024)
Changchun BCHT Biotechnology Co. A's total assets of CN¥5.21 Billion consist of 37.8% current assets and 62.3% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 6.6% |
| Accounts Receivable | CN¥1.41 Billion | 27.1% |
| Inventory | CN¥170.78 Million | 3.3% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥330.60 Million | 6.4% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2017–2024)
This chart illustrates how Changchun BCHT Biotechnology Co. A's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Changchun BCHT Biotechnology Co. A's current assets represent 37.8% of total assets in 2024, a decrease from 44.4% in 2017.
- Cash Position: Cash and equivalents constituted 6.6% of total assets in 2024, down from 11.3% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 6.0% of total assets, a decrease from 9.0% in 2017.
- Asset Diversification: The largest asset category is accounts receivable at 27.1% of total assets.
Changchun BCHT Biotechnology Co. A Competitors by Total Assets
Key competitors of Changchun BCHT Biotechnology Co. A based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Changchun BCHT Biotechnology Co. A - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Changchun BCHT Biotechnology Co. A generates 0.24x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, Changchun BCHT Biotechnology Co. A generates $ 4.46 in net profit.
Changchun BCHT Biotechnology Co. A - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.39 | 2.04 | 1.80 |
| Quick Ratio | 1.20 | 1.85 | 1.58 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥462.96 Million | CN¥ 1.11 Billion | CN¥ 541.56 Million |
Changchun BCHT Biotechnology Co. A - Advanced Valuation Insights
This section examines the relationship between Changchun BCHT Biotechnology Co. A's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.98 |
| Latest Market Cap to Assets Ratio | 0.06 |
| Asset Growth Rate (YoY) | 3.1% |
| Total Assets | CN¥5.20 Billion |
| Market Capitalization | $293.03 Million USD |
Valuation Analysis
Below Book Valuation: The market values Changchun BCHT Biotechnology Co. A's assets below their book value (0.06 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Changchun BCHT Biotechnology Co. A's assets grew by 3.1% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Changchun BCHT Biotechnology Co. A (2017–2024)
The table below shows the annual total assets of Changchun BCHT Biotechnology Co. A from 2017 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥5.20 Billion | +3.14% |
| 2023-12-31 | CN¥5.05 Billion | +17.80% |
| 2022-12-31 | CN¥4.28 Billion | +2.61% |
| 2021-12-31 | CN¥4.17 Billion | +69.18% |
| 2020-12-31 | CN¥2.47 Billion | +55.84% |
| 2019-12-31 | CN¥1.58 Billion | +12.27% |
| 2018-12-31 | CN¥1.41 Billion | +23.39% |
| 2017-12-31 | CN¥1.14 Billion | -- |